8-K: Oncocyte Secures $29.1 Million in Equity Offering to Advance Transplant Assay Program

Oncocyte Corp. announces a $29.1 million equity offering, led by strategic partner Bio-Rad, to fund its transplant assay through FDA clearance and commercial launch.

Summary

• Oncocyte Corporation has entered into securities purchase agreements for a registered direct offering and concurrent private placement, expected to generate $29.1 million in gross proceeds.
• The funding round was led by Oncocyte's five largest shareholders, including strategic partner Bio-Rad Laboratories.
• Bio-Rad has also pledged financial support for the upcoming clinical trial and commercialization efforts.
• The offering proceeds, combined with Oncocyte's existing cash, are intended to fully fund the development of its FDA In-Vitro Diagnostic (IVD) transplant assay program.
• The company sold 3,609,755 shares of common stock in the registered direct offering.
• In the PIPE Offering, the company sold 7,536,708 shares of common stock and pre-funded warrants to purchase 3,069,925 shares of common stock.
• The offerings were priced at $2.05 per share, with no discounts or incentive warrants.
• The closings of the Registered Direct Offering and the PIPE Offering are expected to occur on or about February 10, 2025, subject to customary closing conditions.
• Oncocyte intends to file a registration statement covering the resale of the shares of common stock and shares of common stock underlying the pre-funded warrants to be issued in the PIPE Offering no later than March 15, 2025.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with the successful capital raise and strategic partnership. The focus on FDA clearance and market capture suggests a growth trajectory, but the inherent risks in the biotech industry temper the overall sentiment.

Positives

• The funding is expected to fully fund the development of Oncocyte's FDA IVD transplant assay program, a key milestone for revenue generation.
• Bio-Rad's increased support validates the strategic partnership and the potential of Oncocyte's technology.
• The company's transplant assay aims to improve patient outcomes by providing rapid and reliable results to doctors.
• Early feedback from beta sites indicates that the technology is fast, reliable, and easy to use.
• The company aims to capture share in the $1 billion global transplant testing market.

Risks

• The completion of the PIPE Offering and Registered Direct Offering is subject to customary closing conditions.
• The company's success depends on obtaining FDA clearance for its transplant assay.
• The company faces competition in the $1 billion global transplant testing market.
• The company's future performance is subject to various risks and uncertainties, including market conditions and those outlined in its SEC filings.

Future Outlook

Oncocyte expects rapid adoption of its transplant assay for clinical use at transplant centers across the U.S. following FDA clearance and seeks to capture share in the $1 billion global transplant testing market.

Management Comments

• Josh Riggs, the Company's President and Chief Executive Officer, stated that the funding will help make it easier for transplant doctors to manage their patients' care and that the technology is fast, reliable, and easy to use.
• Andrea James, the Company's Chief Financial Officer, stated that the company is thrilled at the support from existing shareholders in funding their expected future growth and that financial discipline and sound capital stewardship will remain two of their core values going forward.

Industry Context

The announcement highlights Oncocyte's focus on the transplant diagnostics market, which is estimated to be a $1 billion global market. The company's strategic partnership with Bio-Rad and the development of its proprietary transplant assay position it to compete with existing players in the diagnostics industry.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• However, it mentions that Oncocyte's technology can detect signs of kidney transplant rejection more than 11 months sooner than standard protocols, suggesting a potential advantage over existing methods.
• Further information would be needed to assess Oncocyte's competitive position relative to companies like CareDx, Natera, and Thermo Fisher Scientific, which are also involved in transplant diagnostics.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares, but also potential for increased value if the company successfully executes its strategy.
• Employees: Job security and potential for growth within the company.
• Customers (Transplant Centers): Access to a new technology that aims to improve patient care.
• Patients: Potential for improved outcomes through earlier detection of transplant rejection.

Next Steps

• Complete the closing of the Registered Direct Offering and PIPE Offering.
• File a registration statement on Form S-1 covering the resale of shares issued in the PIPE Offering by March 15, 2025.
• Pursue FDA IVD clearance for the transplant assay program.
• Commercial launch of the transplant assay following FDA clearance.

Key Dates

Keywords

Oncocyte, equity offering, transplant assay, FDA IVD clearance, Bio-Rad, registered direct offering, private placement, diagnostics, funding, clinical trial